T1	Participants 394 621	15 centers in France and 1 center in Belgium; 309 patients were randomized to receive either induction therapy with ATG (n=151) followed by initiation of tacrolimus on day 9 or immediate tacrolimus-based triple therapy (n=158).
T2	Participants 852 977	month 12, biopsy-confirmed acute rejections were reported for 15.2% (induction) and 30.4% (noninduction) of patients (P=0.001
T3	Participants 33 100	renal transplant recipients with tacrolimus-based immunosuppression
